TrialThe Journal of infectious diseases2018

A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.

Joanne M Langley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.